Michaël Sébag
McGill University Health Centre · 223 works · 6,002 citations · h-index 32
Top works
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies
- Choroidal blood flow in diabetic retinopathy
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- Identification and Characterization of 1,25-Dihydroxyvitamin D3-responsive Repressor Sequences in the Rat Parathyroid Hormone-related Peptide Gene
- Antisense-mediated inhibition of parathyroid hormone-related peptide production in a keratinocyte cell line impedes differentiation
- Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression.
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
- Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
- Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression.
- Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
- Regulation of parathyroid hormone-related peptide production in normal human mammary epithelial cells in vitro
- Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1
- First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
- Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes